Source:http://linkedlifedata.com/resource/pubmed/id/20814819
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2010-10-4
|
| pubmed:abstractText |
We investigated the association between the risk of locoregional recurrence (LRR) and biological subtypes defined by hormonal receptors (HR) and HER-2 status in women with invasive breast cancer (BC). A total of 618 newly diagnosed BC patients were identified from a cancer registry within a single institution with standardized methods of tumor assessment for estrogen receptor (ER), progesterone receptor (PR), and HER-2. Patients were stratified based on surgical treatment, breast-conserving therapy (BCT) versus modified radical mastectomy (MRM), as well as biological subtypes: HR+/HER-2- (ER-positive or PR-positive, HER-2-negative), HR+/HER-2+ (ER-positive or PR-positive, HER-2-positive), HR-/HER-2+ (ER-negative and PR-negative, HER-2-positive) and TN (ER-negative, PR-negative and HER-2-negative). The association between clinicopathological factors, biological subtype and LRR was evaluated with univariate and multivariate Cox analysis. With a median follow-up of 4.8 years, the rate of LRR was 7.5%. On multivariate analysis, TN, tumor size ?2 cm and lymph node (LN) positivity were associated with increased risk of LRR (P = 0.023, P = 0.048, and P = 0.0034, respectively). In BCT group, HR-/HER-2+ and LN positivity were associated with increased risk of LRR (HR 11.13; 95% CI 2.78-44.53; P = 0.0007 and HR 5.40; 95% CI 1.67-17.43; P = 0.0048, respectively). In MRM group, TN subtype and LN positivity were associated with increased risk of LRR (HR 4.72; 95% CI 1.53-14.52; P = 0.0069 and HR 3.23; 95% CI 1.44-7.29; P = 0.0047, respectively). Compared to HR+/HER-2-, HR-/HER-2+ treated by BCT and TN treated by MRM showed a significant decrease of 5-year LRR free survival (P = 0.0002 and P = 0.002, respectively). Tumor profiling using ER, PR, and HER-2 biomarkers is a promising tool to identify patients at high risk of LRR based on surgical treatment. Our findings suggest a different follow-up and locoregional treatment for patients with HR-/HER-2+ and TN subtypes.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/HER2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1573-7217
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
124
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
187-94
|
| pubmed:meshHeading |
pubmed-meshheading:20814819-Alberta,
pubmed-meshheading:20814819-Breast Neoplasms,
pubmed-meshheading:20814819-Chemotherapy, Adjuvant,
pubmed-meshheading:20814819-Chi-Square Distribution,
pubmed-meshheading:20814819-Disease-Free Survival,
pubmed-meshheading:20814819-Female,
pubmed-meshheading:20814819-Humans,
pubmed-meshheading:20814819-Lymphatic Metastasis,
pubmed-meshheading:20814819-Mastectomy,
pubmed-meshheading:20814819-Neoplasm Invasiveness,
pubmed-meshheading:20814819-Neoplasm Recurrence, Local,
pubmed-meshheading:20814819-Neoplasm Staging,
pubmed-meshheading:20814819-Proportional Hazards Models,
pubmed-meshheading:20814819-Radiotherapy, Adjuvant,
pubmed-meshheading:20814819-Receptor, erbB-2,
pubmed-meshheading:20814819-Receptors, Estrogen,
pubmed-meshheading:20814819-Receptors, Progesterone,
pubmed-meshheading:20814819-Registries,
pubmed-meshheading:20814819-Risk Assessment,
pubmed-meshheading:20814819-Risk Factors,
pubmed-meshheading:20814819-Time Factors,
pubmed-meshheading:20814819-Treatment Outcome,
pubmed-meshheading:20814819-Tumor Markers, Biological
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
|
| pubmed:affiliation |
Department of Radiation Oncology, Cross Cancer Institute and University of Alberta, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada.
|
| pubmed:publicationType |
Journal Article
|